MedTrace Logo

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

NCT03164486 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-02-27

No results posted yet for this study

Summary

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Conditions

  • Breast Carcinoma
  • Colorectal Carcinoma
  • Lung Carcinoma
  • Metastatic Malignant Neoplasm in the Breast
  • Metastatic Malignant Neoplasm in the Colon
  • Metastatic Malignant Neoplasm in the Lung
  • Metastatic Malignant Neoplasm in the Rectum
  • Pancreatic Carcinoma

Interventions

DRUG

18F-αvβ6-BP

Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Julie L. Sutcliffe, Ph.D

    lead OTHER

Principal Investigators

  • Julie Sutcliffe · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03164486 on ClinicalTrials.gov